M4 muscarinic acetylcholine receptor Inhibitors
1 drugsAbout M4 muscarinic acetylcholine receptor
The M4 muscarinic acetylcholine receptor (M4 mAChR) is a G protein-coupled receptor activated by acetylcholine, playing a crucial role in CNS physiological processes. It modulates neuronal excitability, neurotransmitter release, and synaptic plasticity within the central nervous system.
The M4 receptor is a significant target for drug development, particularly for CNS disorders. Currently, there is no genetic evidence data available linking this target to specific diseases, highlighting an area for future investigation.
There is one FDA-approved drug, COBENFY, targeting M4 mAChR, developed by Bristol-Myers Squibb for CNS indications. COBENFY is a small molecule approved in 2024.
Top M4 muscarinic acetylcholine receptor Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting the M4 receptor.
Low competition presents an opportunity for new entrants, but also indicates potential challenges in the target's tractability.
M4 muscarinic acetylcholine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M4 muscarinic acetylcholine receptor, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing treatments.
M4 muscarinic acetylcholine receptor Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M4 muscarinic acetylcholine receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 4 | 0 | 4 | 100% |
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 14 | 8 | 2 | 4 | 80% |
| Phase 4 | 11 | 8 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M4 muscarinic acetylcholine receptor Drug Approval Timeline (2024 - 2024)
The first and only drug, COBENFY, was approved in 2024, marking the beginning of M4-targeted therapies.
Recent approval suggests renewed interest, but long-term success depends on clinical efficacy and market adoption.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 13 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M4 muscarinic acetylcholine receptor. A trial counts if an approved drug acting on M4 muscarinic acetylcholine receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.